Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector

Ben Gary Harvey, Stefan Worgall, Scott Ely, Philip L. Leopold, Ronald Crystal

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

In animals, Ad-mediated gene transfer initiates anti-Ad host immune responses that vary, depending on vector design, dose, host, and transgene. To begin to understand whether the anti-Ad vector responses in humans simulate those in animals, Ad(GV)CD.10, an E1-E3- Ad5 vector encoding the E. coli cytosine deaminase gene, was administered by the intradermal route to six normal individuals (8 x 107 to 8 x 109 particle units, each dose administered to two sites; n = 2 per group). No adverse events were observed. Polymerase chain reaction/Southern analysis demonstrated vector genome in the skin through 28 days in all individuals except one of two at the lowest dose. Local induration, independent of vector dose and baseline systemic anti-Ad5 neutralizing antibodies, developed in all subjects (6 to 17 mm, peak by day 3). Biopsies revealed a mild to moderate T cell (CD3+, CD4+, CD8+), B cell, and macrophage infiltrate at day 3, all decreased by day 28. Langerhans cells accumulated primarily in the papillary dermis. The day 3 cellular response was dose independent. On day 28, CD4+ and CD8+ T lymphocytes and macrophages showed dose dependency. There was minimal systemic Ad5-specific lymphocyte proliferation induced by Ad vector administration in three individuals studied, and no Ad5-specific cytotoxic T lymphocytes (evaluated in two subjects) could be detected. Thus, intradermal administration of an E1-E3- Ad vector to normal subjects induces mild/moderate local cellular responses, even in Ad-immunized individuals. These observations provide a baseline to determine if these human anti-Ad vector host responses can be circumvented by using 'stealth' vectors and/or immunosuppression.

Original languageEnglish
Pages (from-to)2823-2837
Number of pages15
JournalHuman Gene Therapy
Volume10
Issue number17
DOIs
Publication statusPublished - 20 Nov 1999
Externally publishedYes

Fingerprint

Adenoviridae
Cellular Immunity
Macrophages
T-Lymphocytes
Langerhans Cells
Cytotoxic T-Lymphocytes
Dermis
Neutralizing Antibodies
Transgenes
Immunosuppression
Genes
B-Lymphocytes
Genome
Lymphocytes
Biopsy
Polymerase Chain Reaction
Skin
E coli codA protein

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. / Harvey, Ben Gary; Worgall, Stefan; Ely, Scott; Leopold, Philip L.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 10, No. 17, 20.11.1999, p. 2823-2837.

Research output: Contribution to journalArticle

Harvey, Ben Gary ; Worgall, Stefan ; Ely, Scott ; Leopold, Philip L. ; Crystal, Ronald. / Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. In: Human Gene Therapy. 1999 ; Vol. 10, No. 17. pp. 2823-2837.
@article{647d3b86f1cc46ac90064914e5aa14fd,
title = "Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector",
abstract = "In animals, Ad-mediated gene transfer initiates anti-Ad host immune responses that vary, depending on vector design, dose, host, and transgene. To begin to understand whether the anti-Ad vector responses in humans simulate those in animals, Ad(GV)CD.10, an E1-E3- Ad5 vector encoding the E. coli cytosine deaminase gene, was administered by the intradermal route to six normal individuals (8 x 107 to 8 x 109 particle units, each dose administered to two sites; n = 2 per group). No adverse events were observed. Polymerase chain reaction/Southern analysis demonstrated vector genome in the skin through 28 days in all individuals except one of two at the lowest dose. Local induration, independent of vector dose and baseline systemic anti-Ad5 neutralizing antibodies, developed in all subjects (6 to 17 mm, peak by day 3). Biopsies revealed a mild to moderate T cell (CD3+, CD4+, CD8+), B cell, and macrophage infiltrate at day 3, all decreased by day 28. Langerhans cells accumulated primarily in the papillary dermis. The day 3 cellular response was dose independent. On day 28, CD4+ and CD8+ T lymphocytes and macrophages showed dose dependency. There was minimal systemic Ad5-specific lymphocyte proliferation induced by Ad vector administration in three individuals studied, and no Ad5-specific cytotoxic T lymphocytes (evaluated in two subjects) could be detected. Thus, intradermal administration of an E1-E3- Ad vector to normal subjects induces mild/moderate local cellular responses, even in Ad-immunized individuals. These observations provide a baseline to determine if these human anti-Ad vector host responses can be circumvented by using 'stealth' vectors and/or immunosuppression.",
author = "Harvey, {Ben Gary} and Stefan Worgall and Scott Ely and Leopold, {Philip L.} and Ronald Crystal",
year = "1999",
month = "11",
day = "20",
doi = "10.1089/10430349950016555",
language = "English",
volume = "10",
pages = "2823--2837",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "17",

}

TY - JOUR

T1 - Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector

AU - Harvey, Ben Gary

AU - Worgall, Stefan

AU - Ely, Scott

AU - Leopold, Philip L.

AU - Crystal, Ronald

PY - 1999/11/20

Y1 - 1999/11/20

N2 - In animals, Ad-mediated gene transfer initiates anti-Ad host immune responses that vary, depending on vector design, dose, host, and transgene. To begin to understand whether the anti-Ad vector responses in humans simulate those in animals, Ad(GV)CD.10, an E1-E3- Ad5 vector encoding the E. coli cytosine deaminase gene, was administered by the intradermal route to six normal individuals (8 x 107 to 8 x 109 particle units, each dose administered to two sites; n = 2 per group). No adverse events were observed. Polymerase chain reaction/Southern analysis demonstrated vector genome in the skin through 28 days in all individuals except one of two at the lowest dose. Local induration, independent of vector dose and baseline systemic anti-Ad5 neutralizing antibodies, developed in all subjects (6 to 17 mm, peak by day 3). Biopsies revealed a mild to moderate T cell (CD3+, CD4+, CD8+), B cell, and macrophage infiltrate at day 3, all decreased by day 28. Langerhans cells accumulated primarily in the papillary dermis. The day 3 cellular response was dose independent. On day 28, CD4+ and CD8+ T lymphocytes and macrophages showed dose dependency. There was minimal systemic Ad5-specific lymphocyte proliferation induced by Ad vector administration in three individuals studied, and no Ad5-specific cytotoxic T lymphocytes (evaluated in two subjects) could be detected. Thus, intradermal administration of an E1-E3- Ad vector to normal subjects induces mild/moderate local cellular responses, even in Ad-immunized individuals. These observations provide a baseline to determine if these human anti-Ad vector host responses can be circumvented by using 'stealth' vectors and/or immunosuppression.

AB - In animals, Ad-mediated gene transfer initiates anti-Ad host immune responses that vary, depending on vector design, dose, host, and transgene. To begin to understand whether the anti-Ad vector responses in humans simulate those in animals, Ad(GV)CD.10, an E1-E3- Ad5 vector encoding the E. coli cytosine deaminase gene, was administered by the intradermal route to six normal individuals (8 x 107 to 8 x 109 particle units, each dose administered to two sites; n = 2 per group). No adverse events were observed. Polymerase chain reaction/Southern analysis demonstrated vector genome in the skin through 28 days in all individuals except one of two at the lowest dose. Local induration, independent of vector dose and baseline systemic anti-Ad5 neutralizing antibodies, developed in all subjects (6 to 17 mm, peak by day 3). Biopsies revealed a mild to moderate T cell (CD3+, CD4+, CD8+), B cell, and macrophage infiltrate at day 3, all decreased by day 28. Langerhans cells accumulated primarily in the papillary dermis. The day 3 cellular response was dose independent. On day 28, CD4+ and CD8+ T lymphocytes and macrophages showed dose dependency. There was minimal systemic Ad5-specific lymphocyte proliferation induced by Ad vector administration in three individuals studied, and no Ad5-specific cytotoxic T lymphocytes (evaluated in two subjects) could be detected. Thus, intradermal administration of an E1-E3- Ad vector to normal subjects induces mild/moderate local cellular responses, even in Ad-immunized individuals. These observations provide a baseline to determine if these human anti-Ad vector host responses can be circumvented by using 'stealth' vectors and/or immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0033589743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033589743&partnerID=8YFLogxK

U2 - 10.1089/10430349950016555

DO - 10.1089/10430349950016555

M3 - Article

C2 - 10584928

AN - SCOPUS:0033589743

VL - 10

SP - 2823

EP - 2837

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 17

ER -